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,I, Introduction
A. Characteristics of Se
Selenium is a member of the oxygen group of elements; it is primarily anionic but may form
cations in non-aqueous solvents. Its normal oxidation states are selenate, the 6+ form (Se (VI);
selenite, the 4+ (Se (IV); the very transient 2+ form, and the selenide 2 form, to which it is easily
reduced. Pulse radiolysis studies (e.g., Kl&ning and Sehested, 1986) reveal the presence of Se
(V) forms in aqueous selenate/selenites, reflecting the rapid reduction or oxidation of the two
higher forms. The structures of Se clusters have been investigated by Hohl, et aL, (1987).
Selenium is an essential micronutrient; its biochemical functions have been reviewed briefly by
Wendel (1992), and by Burk (1991) and Nve (1991) amongst others. It reduces the toxicities of
Hg, Pb, Cd, Cu, Ni, and As (Cuvinaralar and Furness, 1991; Parizek, 1990; Paulsson and
Lundbergh, 1991; Taketani, et aL, 1991; Ingersoll, et aL, 1990; HSgberg and Alexander, 1986)
and the nephrotoxicity of cisplatin (Baldew, et al., 1991). By contrast, Se deficiency enhances the
nephrotoxicity of cephaloridine, a betalactam antibiotic (Kays, et aL, 1991). It is strongly
nucleophilic in biological systems and usually more reactive in biological molecules than its
sulfur analogues (see, for example, Nosz&l, et aL, 1991).
Table 1
concentration concentration
acyl amine (M)
N,Se-dibenzoylselenocysteine:
8.76 x 10-5 3.38 x 10"1
N,S-dibenzoylcysteamine:
8.76 x 10-5 3.38 x 10"1
kbs sec 1 temperature o C
2.73 x 10.3 29.8
2.31 x 10"5 29.8
In this reaction (Table 1) with n-butylamine the selenocysteamine shows higher reaction rates by
two orders of magnitude (Mautner, 1956); the same relationship holds for Se nucleophilicity over
sulfur in chloroethyl sulfides and selenides (Kang and Spears, 1990). The selenocysteinyl sites of
glutathione peroxidase (GSHPx) demonstrate similarly greater formation constants with methyl
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mercury than the corresponding thiol complexes which were thought to detoxify this form of Hg
(Arnold et aL, 1986). Selenium radicals also react with amino acids by several orders of
magnitude more rapidly than halide or pseudo-halide radicals (Badiello, 1992).
B. AllrOaches in research
For the last forty years, interest in selenium as a drug component has fluctuated, depending
on several factors including the degree to which its chemistry was understood to differ from that
of sulphur, the recognition of its physiological roles, investigations into its mutagenic capacities,
and the degree to which scientists in one discipline were aware of advances made in other fields.
Studies conducted on how organisms in seleniferous environments detoxified Se (Abu-Erreish,
et aL, 1968; Fleming and Alexander, 1975; Chau, et al., 1976;) led to studies on methylation
which in turn have led to the work by Ganther’s group on selenobetaine (see below). The main
commercial non-food use of Se has been in topical applications to counteract dandruff but its
future lies in its anti-tumour and anti-toxic properties.
Selenium work has grown from two general approaches: first, observations from ovine,
bovine and human models show significant correlations between Se levels and physiological
parameters. Secondly, theory-based studies, often within the field of synthetic inorganic
chemistry, exploit the characteristics which place Se in Group VIA of the periodic table, with O,
S, Te and Po. Both approaches tend to exploit the notional analogies between S and Se: for
example, metaI-Se interactions in biology were first investigated as if they were metal-
metallothionein interactions (e.g., Underwood, 1981; Tappel, 1980; Ganther, 1980); theory-based
studies compare the known properties of S compounds with the activities of Se-substituted
molecules, such as the substitution of selenium for chloride in 6-chloropurine ribosides (Mautner,
1956; Mautner, et aL, 1963; Scovill, 1992) or the synthesis of 2-chloro-ethylselenides (Khalil and
Maslat, 1991). The use of Se as a ligand has been exploited more by synthetic inorganic
chemists (e.g., Hoots, et aL, 1984) than by others in the field but its liganding characteristics are
useful in the synthesis of biologically-active molecules.
C. Se metaboli,m
Se normally enters the body in its more oxidised forms, as selenate or selenite, is reduced to
selenide, and is absorbed and/or excreted, depending on Se status, energy demands, dietary
factors (e.g., lipid intake) and the toxic or heavy-metal burden carried by the organism. Selenite
and selenious acid are toxic; its most oxidised state, selenate, is non-toxic. In normal
metabolism, selenate reduction occurs via GSH to selenite which is then more quickly reduced
by GSH reductase and/or methylation, as shown by the following equations (Table 2),
summarised in Whiting, et aL, (1980).
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Table 2
(1) HSeO4" + 2GSH--> HSeO3" + GS-SG + H20
(2) HSeO + 4GSH --> GS-Se-SG + GS-SG + OH" + 2H20
(3) GS-Se-SG + GSH <--> GS-Se" + GS-SG + H+
(4) GS-Se-SG + NADPH --> GS-Se + GSH + NADP+
glutathione reductase
(5) GS-Se + H20 <m> SeO + GSH + OH"
(6) GS-Se- + NADPH + H20--> HSe- + GSH + NADP+ + OH
glutathione reductase
(7) GS-Se" + GSH <---> HSe" + GS-SG
(8) HSe + [O]---> Se + OH"
(9) HSe + [O] + 2GSH --> HSe" + GS-SG + H20
Selenate reduction by GSH and other sulfhydryl compounds is shown in Eqo 1; selenite reduction
(Eq. 2) and further reactions take place in seconds. Reduction of selenite proceeds via the
selenotrisulfide (GS-Se-SG) which is relatively stable, and via the persulfide, (GS-Se) which is
highly reactive. Selenide is protected against oxidation (Eq. 8) by the presence of excess
sulfhydryls (Eq. 9).
Protein incorporation may follow, or the product may be excreted after the formation of di- or
trimethylselenides. The formation of methylated products, and the route of excretion, depends on
the organism, on the form of selenium in the exposure, on the amount of selenium in the dose,
on the selenium status of the organism, and on the presence of interactive factors, such as the
sex of the animal, its hormone status (especially pregnancy or lactation in females), and the
heavy-metal body load (e.g., Janghorbani, et aL, 1991; Parizek, 1990). That these interactive
factors have a bearing on the use of Se in pharmaceuticals may be obvious; it is also significant
that the selenobetaine synthetics, in bypassing the hydrogen selenide pool, may bypass at least
some of these metabolic interactions which can potentiate Se or interaction factor toxicities.
II. Se in bioloaical materials
A, Selenocysteine
Selenium may be most familiar through knowledge of the consequences of nutritional deficits,
or through its role as the catalytic moiety of glutathione peroxidase. These concepts are related
in that Se deficiency lowers GSHPx levels and activity with severe consequences for the
organism. Briefly put, Se in GSHPx appears as a selenocysteine molecule, probably located at
the N-terminal ends of alpha helices in what Epp, et a/., (1983) postulate as a rather rigid beta-
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alpha-beta structure. The main reaction of the catalytic cycle shuttles between the selenolate and
seleninic acid state of selenocysteine. Selenocysteine biosynthesis, starting from a serine
moiety, is genetically directed via a TGA stop codon. Bock, et al., (1991) proposed that the
evidence presented by them and by the Stadtman group at the National Institutes of Health (e.g.,
Stadtman, 1990; Politino, et al., 1991) justified the recognition of Se-cys as the 21st amino acid,
using U as the symbol in the one-letter amino acid code. This convention is now fairly
widespread in the relevant literature.
B, Protein binding
A number of issues inform the questions surrounding Se chemistry and biochemistry, and
thus its pharmacology: these include the formation of Se proteins, and the inorganic chemistry of
selenium in vivo. It is commonly held that Se incorporation occurs as a result of non-specific
processes involving random substitution of Se for S during protein synthesis. For
selenocysteine, this is not the case, and the general chemistry of selenoprotein formation is still
poorly understood. The locations and characteristics of Se-binding proteins continue to be
defined as Se-responsive conditions are proposed or verified. Of the number of other
selenoproteins reported in the literature, and since the publication of the genetic encoding of Se-
cys production, some of them have been examined for the TGA codon e.g., Hsu and Eckhert,
1991; Pumford, et aL, 1992), which has not been found.
Microvascular damage induced by sucrose has been reported to respond to Se
supplementation: investigating this, Hsu and Eckhert (1991) report that in kidney microvascular
nuclei over 90% of the radioselenium activity found was associated with the nucleus, and that of
the two 22kDa proteins, one was associated with the nonhistone chromosomal fraction and the
other with the nuclear protein matrix. That of the matrix was 73% homologous wtlq bovine
pancreatic ribonuclease; the protein associated with the chromosomal fraction had no trace
homologies but had an N-terminal block.
The literature is more specific about binding in the liver, where GSHPx synthesis occurs and
where over 70% of human GSHPx is found. A protein found in mouse liver binding a
(hepatotoxic) reactive metabolite of acetominophen (Pumford, et al, 1992) has been found to be
97% homologous with a non-selenocysteine selenium-binding protein of 56 kDa (Kang and
Spears, 1990). It is not known if the acetominophen metabolite binds to a selenol or selenide
moiety of the protein or to the cysteinyl sulfhydryl groups. The role of Se in decreasing
acetominophen hepatotoxicity is not agreed. Pumford and co-workers suggest that it contains a
number of highly nucleophilic sites which scavenge electrophiles not detoxified by glutathione.
It is curious, however, that as late as 1991, Bock’s group were able to publish a statement
that "it is still not known how selenite enters the cell and how it is reduced to selenide" (Bock, et
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aL, 1991: 516). In 1983, Epp, et al., were willing to write in reference to GSHPx that ’traces of
alimentary selenium provide the prosthetic group, a selenocysteine residue’. The 1978 reference
by Forstrom and others which they cited is not categorical or definitive about how alimentary Se
is converted to selenocysteine, whether the initial Se is inorganic or a component of for
example selenomethionine, a common selenoprotein found in whole grains. Forstrom suggests
that selenocysteine could be synthesised in vivo from selenomethionine via selenocystathionine
(Forstrom et aL, 1978); or, in the presence of GSH and GSH reductase, a cysteine-synthase-like
reaction (Olson and Palmer, 1976) could take place with hydrogen selenide. Later investigations
(e.g., Whanger et al., 1991) indicate that the plasma Se of rats, monkeys, sheep and humans
was associated predominantly with selenoprotein P, and that the association of Se with albumin
was dependent on the selenomethionine content of the diet.
C. Mtgenic and clastogenic activity of Se
The organo-Se compounds tested by Ganther’s group give negative results in genotoxicity
tests. Others investigating organoselenium (e.g., Kang and Spiers, 1990; Cotgreave, et aL,
1991; eI-Bhayoumi, et al., 1992); the 2-chloroethylselenides synthesised by Kang and Spears are
more than two orders of magnitude higher in nucleophilicity than their sulphur analogues. Czyrski
and Inglot (1991) demonstrate the mitogenicity of some organo-Se compounds; Khalil and
Muslat (19901) Chromosomal aberrations, undetectable by the [then available] cytogenic method
may be induced by lower doses of Se than those administered by Norppa, et aL, (1980a-c), as
they observed. Their tests were negative in bone marrow or primary spermatocytes of mice after
i.p. injection of 0.8 mg/kg bd.wt.; on CH bone marrow, 0.3-6.0 mg/kg bd.wt, injections of sodium
selenite induced SCE and aberrations at the 3-6 mg/kg dose range. Sirianni and Huang (1983),
testing 0-64 I.tg/ml of NaSeO32-, NaSeO42- and HSe2- with and without $9, found the lower
oxidation states induced more SCE than selenate in the CH V79 cell line. Ray (1984), measuring
SCE induced by doses of [7.95 x 10-6] M NaSeO32-, found that reduced glutathione was
required for conversion of selenite to its SCE-inducing form, suggesting that this conversion runs
on the same pathway as normal RBC metabolism of sodium selenite. Anjaria and Madhvanath
(1988) noted that the presence of glutathione enhanced the selenite-induced genotoxicity in the
yeast BZ34. The rate of genetic damage rose and then fell over the period of their five-hour
experiments.
Kramer and Ames (1988), Hung, et al., (1988) and Garberg, et al., (1988) have demonstrated
that selenite genotoxicity is a function of oxidative damage. Kramer and Ames ascribe this to the
reaction of intracellular thiols and selenite, producing peroxide and superoxide radicals; Garberg
minor corrigendum appeared in Mutation Res. (1991) 242,7: 293.
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and co-workers found that DNA fragmentation was inhibited by cyanide and mercuric chloride.
Hung and co-workers found a significant protective effect against oxidative single-strand breaks
(SSB) at the lower concentrations of 10-5-10-7 M NaSeO32-, but a significant damaging effect
at 10-4 M NaSeO32- Balansky (1991) uses his battery of tests results, including a two week
challenge to rats and mice of 10 ppm NaSeO32- in the drinking water, to assign a rdle of
comutagen and co-clastogen to selenite. Selenium is thus an oxidant and an anti-oxidant in
biological systems, depending on its form, route of entry into metabolism, and its co-occurrence
with other factors.
III. Selenium activity in anti-tumour accents
A. Henry Mautner: Yale
Early developments of Se antitumour agents took place in the late 1950’s and early 1960’s
through Henry Mautner’s work in the Department of Pharmacology at Yale. By using the
development of S-analogues of naturally-occurring purine and pyramidine bases e.g., 6-
mercaptopurine, 6-methylmercaptopurine and 2-thiouracil- as paradigms, Mautner synthesised a
number of compounds between 1956 and 1962: 6-Se-purine, 6-Me-Se-purine, 2-selenouracil,
2,4-diselenouracil, 2-selenothymine (Mautner, 1956); and later, selenoguanine, diselenothymine,
and 5-methylcytosine (Mautner, et al., 1963). 6-Se-purine was prepared by the addition of
sodium hydrogen selenide to 6-chloropurine; a similar reaction adding selenourea produced a
92% yield. The selenouracils were synthesised using selenourea instead of thiourea in the then-
standard uracil synthetic methods.
Hypoxanthine (oxypurine), mercaptopurine and the 6-selenpurine were methylated, producing
hypsochromic shifts in UV absorption with increasing atomic number, and an increase in acidity
of the compounds. The polarisability of the carbonyl, thiocarbonyl and selenocarbonyl bonds
increases in passing up the periodic table.
Of these compounds, the selenopurine, tested on the growth of mouse lymphoma L-1210
cells, demonstrated a level of activity equivalent to that of 6-mercaptopurine, then in use as a
clinical anti-leukaemic agent. In other mouse tumour studies the thiopurine was more active. On
the other hand, the selenopurine was more anti-bacterial and had a greater ability to inhibit
formate incorporation into purines than the sulphur analogue. 6-selenopurine was also found to
have Cu-chelating properties equal to those of 8-hydroxyquinoline and exceeding those of
hypoxanthine. In an effort to improve the performance and stability of the selenopurine,
Mautner’s group (Mautner, et al., 1963) made selenoguanine as an analogue of 6-thioguanine
and compared this activity against implanted L5178Y lymphoma in mice, in 6C3HED
lymphosarcoma cell lines, and in mice bearing an ascites cell form of sarcoma 180. In the latter
case the selenoguanine produced tumour inhibition over a wider dose range; in the former whilst
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both thioguanine and selenoguanine were inhibitory, selenoguanine was the least toxic of the
two. Selenocytosine was compared with thiocytosine as an anti-tumour agent, but neither
compound significantly prolonged the survival time of mice implanted with the L5178Y
lymphoma.
Mautner also studied the effects of Se-substitution on the lipophilicity of phenobarbital, a 2-
selenobarbiturate (Mautner and Clayton, 1959), and compared the transacylation rates of
thioacyl and selenoacyl analogs in reaction with n-butylamine (Mautner and G0nther, 1961). Se
substitution of O in phenobarbital increased the drug’s lipophilicityoFrom this structure, GQnther,
et al., (1992) have developed model photosensitising merocyanine dyes with a circa 100-fold
enhancement of photogeneration efficiency for singlet oxygen.
B. Howard Ganther. Wisconsin
Howard Ganther and his group have worked on Se metabolism for over thirty years; their
earliest work concerned agricultural herbivore metabolism of Se. Herbivores rely on plants, and
therefore soils, for their trace element nutrition, and the primary concerns of Se research were
those of deficiency manifested in cardiac myopathy and so-called ’white muscle disease’- and
of excess, manifested in ’blind staggers’- neurological and skeletal muscle impairment- and
sloughing of hooves and other keratinised tissues. The principal concern was the detoxifying of
Se through methylation Nahapetian, et al., 1983; McConnell and Portman, 1952; Obermeyer,
et ai., 1971; Foster, et al., 1986); the production of hydrogen selenide was considered to be the
intoxifying step in Se toxicity. The forms of Se most productive of MeSe were investigated for
many years; in the course of these it was noted (Foster, et. al., 1986b) that trimethylselenium
could not be formed from selenobetaine by decarboxylation.
Methyl compounds were long held to be biologically inactive. However, two further types of
discoveries have led to the present state of selenobetaine cytotoxins. First, methylated species
can be remobilised by demethylation, in soils (Oremland, et aL, 1990); in vivo,
trimethylselenonium ion, via betaine:homocysteine methyltransferase, can be demethylated to
form dimethyl selenide and methione (Goeger and Ganther 1993). Secondly, whilst in theory
methylated species should be active through their increased lipophilicity, no evidence of this was
found until 1989, when Ganther’s group reported an observation that methyI-Se was found in
mouse kidney, where they didn’t expect it (Stadtman, 1990). They also reported a synergistic
toxicity between arsenite and methyl-Se compounds (Kraus and Ganther, 1989). In normal tissue
seven organo-Se compounds were shown to be toxic when administered with arsenite (Table 3)
and this toxicity held true for tumour suppression in dimethylbenz(a)anthracene induced
mammary tumours in rats (Ip and Ganther, 1990).
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Table 3
Methylseleninic acid (2 mg Se/kg)
Dimethylselenoxide (2 mg Se/kg)
Trimethylselenonium chloride (3 mg Se/kg)
Selenobetaine (2 mg Se/kg)
Selenobetaine methyl ester (2, 1, and 0.5 mg Se/kg)
Se-methylselenocysteine (2 mg Se/kg)
Selenomethionine (2 mg Se/kg)
In a later study (Ip and Ganther, 1992), the arsenite addition was dropped, and paired S/Se
compounds were tested for DMBA-induced tumour suppression (cysteamine/selenocystamine;
sulfobetaine/selenobetaine; S-methylcysteine; Se-methylselenocysteine). In the sulfur series,
only cysteamine and S-methylcysteamine produced anticancer activity, and the levels required
for these responses were 500-750 times as high as those of the corresponding Se analogues.
IV, Conclusions
The mechanisms of Se genotoxicity both for normal and tumour cells are not settled, but it is
established that an inverse relationship exists between Se content of soils and water and the
incidence of human tumours. Ganther’s group (Wilson, et aL, 1992) take the view that DNA
fragmentation resulting from selenite exposure occurs during reductive metabolism and not from
an accumulation of the methylated by-product. The methylated compounds alter the long-term
proliferative potential of cells via mechanisms distinct from those associated with cell injury and
death by necrosis. Se supplementation can inhibit tumorigenesis in rats, depending on the dose
of the carcinogen and dietary fat intake (Ip, 1981). Banner and others (1981) found that pre-
treatment with sodium selenite did not reverse or inhibit the acute inhibition of RNA and DNA
synthesis induced by methyl-azoxymethanol (MAM); they conclude that Se exerts its protective
effect by some mechanism other than interference with carcinogen activation by microsomes.
Balansky (1991, 1992) has published two papers which he feels show conclusively that both Se
genotoxicity and its antitumour effects are a function of timing of dose and the presence or
absence of possible comutagens. It is clear that the exploitation of the reactivity of selenium
must be mediated by the properties of its carrier molecules, and by a better understanding of its
metabolic chemistry. This is impossible without better communication between
structural/analytical chemists and biological chemists of their respective investigations and their
results.
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